Leukemia Clinical Trial
Official title:
Randomized Study Of Fludarabine And Cyclophosphamide With Or Without Genasense (Bcl-2 Antisense Oligonucleotide) In Subjects With Relapsed Or Refractory Chronic Lymphocytic Leukemia
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing
so they stop growing or die. Oblimersen may help fludarabine and cyclophosphamide kill more
cancer cells by making them more sensitive to the drugs. It is not yet known if fludarabine
and cyclophosphamide are more effective with or without oblimersen.
PURPOSE: Randomized phase III trial to compare the effectiveness of fludarabine and
cyclophosphamide with or without oblimersen in treating patients who have relapsed or
refractory chronic lymphocytic leukemia.
OBJECTIVES:
- Compare the complete response and nodular partial response of patients with relapsed or
refractory chronic lymphocytic leukemia treated with fludarabine and cyclophosphamide
with or without oblimersen.
- Compare the overall response rate, response duration, survival, and time to progression
in patients treated with these regimens.
- Compare the clinical benefit and safety of these regimens in these patients.
OUTLINE: This is a randomized, open-label, multicenter study. Patients are stratified
according to disease response to prior fludarabine-containing therapy (responsive vs
refractory), number of prior regimens (1-2 vs 3 or more), and duration of response to last
prior therapy (more than 6 months vs 6 months or fewer). Patients are randomized to 1 of 2
treatment arms.
- Arm I: Patients receive oblimersen IV continuously on days 1-7 via an infusion pump
(ending on day 8) and fludarabine IV over 20-30 minutes and cyclophosphamide IV over
30-60 minutes on days 5-7. Patients also receive filgrastim (G-CSF) subcutaneously (SC)
beginning on day 11 and continuing until blood counts recover.
- Arm II: Patients receive fludarabine IV over 20-30 minutes followed by cyclophosphamide
IV over 30-60 minutes on days 1-3. Patients also receive G-CSF SC beginning on day 7
and continuing until blood counts recover.
Treatment in both arms continues every 28 days for up to 6 courses in the absence of disease
progression or unacceptable toxicity.
Patients are followed at 1 month and then every 2 months for 2 years.
PROJECTED ACCRUAL: A total of 200 patients (100 per arm) will be accrued for this study
within 1 year.
;
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05691608 -
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
|
N/A | |
| Recruiting |
NCT04092803 -
Virtual Reality as a Distraction Technique for Performing Lumbar Punctures in Children and Young Adu
|
N/A | |
| Active, not recruiting |
NCT02530463 -
Nivolumab and/or Ipilimumab With or Without Azacitidine in Treating Patients With Myelodysplastic Syndrome
|
Phase 2 | |
| Completed |
NCT00948064 -
Vorinostat in Combination With Azacitidine in Patients With Newly-Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
|
Phase 2 | |
| Completed |
NCT04474678 -
Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")
|
N/A | |
| Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03948529 -
RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation
|
Phase 2 | |
| Completed |
NCT01682226 -
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
|
Phase 2 | |
| Completed |
NCT00003270 -
Chemotherapy, Radiation Therapy, and Umbilical Cord Blood Transplantation in Treating Patients With Hematologic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02723994 -
A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia
|
Phase 2 | |
| Terminated |
NCT02469415 -
Pacritinib for Patients With Lower-Risk Myelodysplastic Syndromes (MDS)
|
Phase 2 | |
| Recruiting |
NCT04856215 -
90Y-labelled Anti-CD66 ab in Childhood High Risk Leukaemia
|
Phase 2 | |
| Recruiting |
NCT06155188 -
Post-transplant PT/FLU+CY Promotes Unrelated Cord Blood Engraftment in Haplo-cord Setting in Childhood Leukemia
|
N/A | |
| Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
| Active, not recruiting |
NCT04188678 -
Resiliency in Older Adults Undergoing Bone Marrow Transplant
|
N/A | |
| Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
| Completed |
NCT01212926 -
Early Detection of Anthracycline Cardiotoxicity by Echocardiographic Analysis of Myocardial Deformation in 2D Strain
|
N/A | |
| Terminated |
NCT00014560 -
Antibody Therapy in Treating Patients With Refractory or Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
| Recruiting |
NCT04977024 -
SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer
|
Phase 2 | |
| Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A |